Home > Rheumatology > EULAR 2018 > Systemic Sclerosis and Systemic Lupus Erythematosus > Promising Results Rituximab in Systemic Sclerosis, and Systemic Lupus Erythematosus Classification Criteria

Promising Results Rituximab in Systemic Sclerosis, and Systemic Lupus Erythematosus Classification Criteria

Presented By
Prof. Allanore, University of Paris Descartes University, France
Conference
EULAR 2018

Promising results rituximab in systemic sclerosis

The largest study of use in routine care of rituximab in patients with SSc showed significant changes on skin fibrosis but not on lung fibrosis. The safety profile was considered good and future studies are warranted into the possible role of rituximab in this patient population.

According to Prof. Allanore, (University of Paris Descartes University, France), a few small-sized observational studies have suggested that rituximab is a promising treatment in patients suffering from SSc. The study aimed to evaluate the outcomes of SSc patients receiving in routine care rituximab.

This was done as a retrospective longitudinal multicentre observational study in which eligible SSc patients were treated with rituximab upon the decision of their physician within the framework of European Scleroderma Trials and Research group (EUSTAR). This is an international scleroderma research network that aims to f...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on